サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1779742

細胞のリプログラミングの世界市場

Cell Reprogramming

出版日
ページ情報
英文 369 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
細胞のリプログラミングの世界市場
出版日: 2025年07月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 369 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

細胞のリプログラミングの世界市場は2030年までに6億1,160万米ドルに達する見込み

2024年に3億9,450万米ドルと推定される細胞のリプログラミングの世界市場は、2030年には6億1,160万米ドルに達し、分析期間2024-2030年のCAGRは7.6%で成長すると予測されます。本レポートで分析したセグメントの一つであるmRNAリプログラミング技術は、CAGR8.4%を記録し、分析期間終了時には3億4,190万米ドルに達すると予測されます。エピソーム・リプログラミング技術分野の成長率は、分析期間中CAGR 7.1%と推定されます。

米国市場は1億750万米ドルと推定、中国はCAGR12.0％で成長すると予測

米国の細胞のリプログラミング市場は、2024年に1億750万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億3,060万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは12.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.8％と7.3％と予測されています。欧州では、ドイツがCAGR 5.0%で成長すると予測されています。

世界の細胞のリプログラミング市場- 主要動向と促進要因のまとめ

細胞のリプログラミングは再生医療をどう変えるか？

細胞のリプログラミングは、再生医療における画期的なアプローチとして登場し、分化細胞を多能性幹細胞に変換することを可能にしました。この画期的な技術は、変性疾患、臓器不全、遺伝性疾患の治療に計り知れない可能性を秘めています。研究者たちは、損傷した組織を修復し、臓器を再生するために細胞のアイデンティティを操作する新しい方法を模索しており、個別化医療への応用が期待されています。CRISPR-Cas9のような遺伝子編集技術の進歩は、細胞のリプログラミングの精度と効率をさらに高めています。より安全で効果的な初期化法の開発は臨床応用を加速させ、現代の再生療法の要となっています。研究が進むにつれ、細胞のリプログラミングの市場は急速に拡大しています。

なぜ細胞のリプログラミングの需要が高まっているのか？

神経変性疾患、心血管疾患、がんなどの慢性疾患の有病率の増加により、革新的な治療アプローチへの需要が高まっています。細胞のリプログラミングは、身体自身の細胞機構を利用して機能を回復させることにより、従来の治療に代わる実行可能な選択肢を提供します。また、移植や薬剤試験のために患者特異的な細胞を作製する能力も、製薬会社や研究機関の関心を高めています。さらに、拡大する組織工学と3Dバイオプリンティングの分野では、創薬や毒性試験のための機能的組織モデルの開発に細胞のリプログラミングが活用されています。規制の枠組みがこれらの新たな治療法に対応できるように進化するにつれて、臨床試験やトランスレーショナルリサーチへの投資が増加し、市場導入が加速すると予想されます。

細胞のリプログラミング市場をリードしている地域は？

北米が細胞のリプログラミング市場を独占しており、強力な研究資金、高度なヘルスケアインフラ、大手バイオテクノロジー企業の存在がその原動力となっています。特に米国は、幹細胞研究と再生医療の最前線にあり、細胞のリプログラミングに関する画期的な調査を行っている機関がいくつかあります。欧州もこれに続き、ドイツ、英国、フランスなどの国々が細胞治療や再生医療イニシアティブに多額の投資を行っています。一方、アジア太平洋地域は、政府支援の増加、バイオテクノロジー新興企業の拡大、学術機関と業界関係者の協力関係の高まりにより、急成長を遂げています。日本や中国のような国々が幹細胞研究で大きく前進しており、市場拡大をさらに後押ししています。

市場成長を促す主な要因とは？

細胞のリプログラミング市場の成長は、遺伝子編集の進歩、再生医療への投資の増加、個別化ヘルスケアへの応用拡大など、いくつかの要因によって牽引されています。創薬のための疾患特異的モデルを生成できるようになったことで、医薬品の研究開発は一変し、標的療法の開発が加速しています。さらに、調査における人工知能と機械学習の統合は、データ分析を強化し、リプログラミング技術を最適化しています。再生治療の需要が高まり、幹細胞研究を取り巻く倫理的な懸念が薄れるにつれて、細胞のリプログラミング市場は今後数年間で持続的な成長を遂げる見通しです。

セグメント

技術（mRNAリプログラミング技術、エピソームリプログラミング技術、センダイウイルスベースのリプログラミング技術、その他の技術）、用途（調査用途、治療用途）、最終用途（研究・学術機関、バイオテクノロジー・製薬企業）

調査対象企業の例

  • Asgard Therapeutics AB
  • Aspen Neuroscience
  • Astellas Pharma Inc.
  • Autolus Therapeutics
  • Beam Therapeutics
  • bit.bio
  • BlueRock Therapeutics
  • Capricor Therapeutics
  • Cell Reprogramming & Therapeutics LLC
  • Century Therapeutics
  • Colossal Biosciences
  • CRISPR Therapeutics AG
  • Editas Medicine
  • Fate Therapeutics
  • Fujifilm Cellular Dynamics, Inc.
  • Graphite Bio
  • Healios K.K.
  • Intellia Therapeutics
  • Lyell Immunopharma
  • Mogrify Limited

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP29873

Global Cell Reprogramming Market to Reach US$611.6 Million by 2030

The global market for Cell Reprogramming estimated at US$394.5 Million in the year 2024, is expected to reach US$611.6 Million by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. mRNA Reprogramming Technology, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$341.9 Million by the end of the analysis period. Growth in the Episomal Reprogramming Technology segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$107.5 Million While China is Forecast to Grow at 12.0% CAGR

The Cell Reprogramming market in the U.S. is estimated at US$107.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$130.6 Million by the year 2030 trailing a CAGR of 12.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Cell Reprogramming Market - Key Trends & Drivers Summarized

How Is Cell Reprogramming Transforming Regenerative Medicine?

Cell reprogramming has emerged as a revolutionary approach in regenerative medicine, enabling scientists to convert differentiated cells into pluripotent stem cells. This breakthrough technology holds immense potential for treating degenerative diseases, organ failure, and genetic disorders. Researchers are exploring new ways to manipulate cellular identity to repair damaged tissues and regenerate organs, offering promising applications in personalized medicine. Advancements in gene editing techniques, such as CRISPR-Cas9, have further enhanced the precision and efficiency of cell reprogramming. The development of safer and more effective reprogramming methods is accelerating clinical applications, making it a cornerstone of modern regenerative therapies. As research continues to uncover novel pathways for cellular transformation, the market for cell reprogramming is set for rapid expansion.

Why Is the Demand for Cell Reprogramming Increasing?

The increasing prevalence of chronic diseases, including neurodegenerative conditions, cardiovascular disorders, and cancer, is driving demand for innovative therapeutic approaches. Cell reprogramming offers a viable alternative to traditional treatments by harnessing the body’s own cellular machinery to restore function. The ability to generate patient-specific cells for transplantation and drug testing is also fueling interest among pharmaceutical companies and research institutions. Additionally, the expanding field of tissue engineering and 3D bioprinting is leveraging cell reprogramming to develop functional tissue models for drug discovery and toxicity testing. As regulatory frameworks evolve to accommodate these emerging therapies, increased investment in clinical trials and translational research is expected to accelerate market adoption.

Which Regions Are Leading the Cell Reprogramming Market?

North America dominates the cell reprogramming market, driven by strong research funding, advanced healthcare infrastructure, and the presence of leading biotechnology firms. The United States, in particular, is at the forefront of stem cell research and regenerative medicine, with several institutions conducting groundbreaking studies on cell reprogramming. Europe follows closely, with countries such as Germany, the UK, and France investing heavily in cellular therapies and regenerative medicine initiatives. Meanwhile, the Asia-Pacific region is witnessing rapid growth due to increasing government support, expanding biotech startups, and rising collaborations between academic institutions and industry players. Countries like Japan and China are making significant strides in stem cell research, further propelling market expansion.

What Are the Key Factors Driving Market Growth?

The growth in the cell reprogramming market is driven by several factors, including advancements in gene editing, increasing investment in regenerative medicine, and expanding applications in personalized healthcare. The ability to generate disease-specific models for drug discovery is transforming pharmaceutical R&D, leading to the accelerated development of targeted therapies. Furthermore, the integration of artificial intelligence and machine learning in cell reprogramming research is enhancing data analysis and optimizing reprogramming techniques. As the demand for regenerative treatments rises and ethical concerns surrounding stem cell research diminish, the market for cell reprogramming is poised for sustained growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Cell Reprogramming market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming, Other Technologies); Application (Research Application, Therapeutic Application); End-Use (Research and Academic Institutes, Biotechnology and Pharmaceutical Companies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • Asgard Therapeutics AB
  • Aspen Neuroscience
  • Astellas Pharma Inc.
  • Autolus Therapeutics
  • Beam Therapeutics
  • bit.bio
  • BlueRock Therapeutics
  • Capricor Therapeutics
  • Cell Reprogramming & Therapeutics LLC
  • Century Therapeutics
  • Colossal Biosciences
  • CRISPR Therapeutics AG
  • Editas Medicine
  • Fate Therapeutics
  • Fujifilm Cellular Dynamics, Inc.
  • Graphite Bio
  • Healios K.K.
  • Intellia Therapeutics
  • Lyell Immunopharma
  • Mogrify Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Cell Reprogramming - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Breakthroughs in iPSC Technology Propel Growth of Personalized Medicine Applications
    • Growing Demand for Patient-Derived Cell Models Drives Cell Reprogramming Research
    • Expansion of Drug Discovery and Disease Modeling Markets Boosts Adoption of Reprogramming Techniques
    • Technological Innovations in Gene Editing Strengthen Cell Reprogramming Precision and Efficiency
    • Rising Interest in Anti-Aging and Regenerative Medicine Spurs Scientific Exploration
    • Increased Focus on Cell-Based Therapeutics Fuels Investment in Reprogramming Platforms
    • Advancements in 3D Cell Culture and Organoid Development Enhance Market Potential
    • Emergence of AI and Automation Tools Streamlines Cell Reprogramming Workflows
    • Growing Academic and Commercial Collaborations Drive Translational Research
    • Rising Adoption of Reprogramming Techniques in Toxicology and Safety Screening Expands End-Use Applications
    • Development of Non-Integrating Reprogramming Methods Enhances Clinical Viability
    • Use of Reprogrammed Cells in Rare Disease Research Generates New Opportunities
    • Demand for Personalized Cell Lines in Oncology Accelerates Market Adoption
    • Increasing Government and Private Sector Funding Propels R&D in Cellular Engineering
    • Integration with Synthetic Biology Expands Future Therapeutic Possibilities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cell Reprogramming Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cell Reprogramming by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cell Reprogramming by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Cell Reprogramming by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for mRNA Reprogramming Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for mRNA Reprogramming Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for mRNA Reprogramming Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Episomal Reprogramming Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Episomal Reprogramming Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Episomal Reprogramming Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Sendai Virus-based Reprogramming by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Sendai Virus-based Reprogramming by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Sendai Virus-based Reprogramming by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Therapeutic Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Therapeutic Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Therapeutic Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Research & Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Research & Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Research & Academic Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Biotechnology & Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Biotechnology & Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Biotechnology & Pharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • JAPAN
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • CHINA
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • EUROPE
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Cell Reprogramming by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Cell Reprogramming by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Cell Reprogramming by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • FRANCE
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • GERMANY
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Cell Reprogramming by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Cell Reprogramming by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Cell Reprogramming by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • INDIA
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Cell Reprogramming by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Cell Reprogramming by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Cell Reprogramming by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Cell Reprogramming by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Cell Reprogramming by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Cell Reprogramming by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030
  • AFRICA
    • Cell Reprogramming Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Cell Reprogramming by Technology - mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Cell Reprogramming by Technology - Percentage Breakdown of Value Sales for mRNA Reprogramming Technology, Episomal Reprogramming Technology, Sendai Virus-based Reprogramming and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Cell Reprogramming by Application - Research Application and Therapeutic Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Cell Reprogramming by Application - Research Application and Therapeutic Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Cell Reprogramming by Application - Percentage Breakdown of Value Sales for Research Application and Therapeutic Application for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Cell Reprogramming by End-Use - Research & Academic Institutes and Biotechnology & Pharmaceutical Companies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Cell Reprogramming by End-Use - Percentage Breakdown of Value Sales for Research & Academic Institutes and Biotechnology & Pharmaceutical Companies for the Years 2015, 2025 & 2030

IV. COMPETITION